Table TABLE.

 Summary of Completed BNP Surrogate End Point Studies and Ongoing Clinical End Point Trials

Study Acronym	Patient Population	Outcome Measure
ALLAY	Hypertensive with LV hypertrophy	LV mass
ALOFT	Hypertensive with class II to IV heart failure	BNP + NT‐proBNP
AVOID	Hypertensive type II diabetes with proteinuria	UACR
ASPIRE	Post‐MI with systolic dysfunction	LV remodeling
ALTITUDE	Type II DM with CVD and/or DM nephropathy	Time to first event—CV death/MI
		ESRD
		Doubling serum creatinine
APOLLO	Normal and hypertensive elderly patients	Prevention of CV end points
ASTRONAUT	Acute heart failure	Time to first event—CV death
		Hospitalization
ATMOSPHERE	Chronic systolic heart failure	Time to first event—CV death
		Hospitalization

Abbreviations: BNP, brain natriuretic protein; CV, cardiovascular; DM, diabetes mellitus; ESRD, end‐stage renal disease; LV, left ventricular; MI, myocardial infarction; NT proBNP, N‐terminal proBNP; UACR, urinary albumin creatinine ratio.